Autoimmune Connection in Vitiligo and Erythema Annulare Centrifugum

Introduction to Autoimmune Connection

Autoimmunity is the most common underlying cause linking vitiligo and erythema annulare centrifugum, with thyroid autoimmune disease being a particularly important association to investigate 1, 2

Autoimmune thyroid disease is found in approximately 34% of adults with vitiligo, making it one of the most common associations 2
The British Journal of Dermatology guidelines specifically recommend checking thyroid function in vitiligo patients due to this high prevalence of autoimmune thyroid disease 1
Vitiligo presents as depigmented patches that are often symmetrical and increase in size over time, corresponding with loss of functioning epidermal melanocytes 2
Common sites for vitiligo include fingers, wrists, axillae, groins, and body orifices such as mouth, eyes, and genitalia 2
When both conditions are present, screening for underlying autoimmune disorders is essential, particularly thyroid disease 1

For vitiligo diagnosis, Wood's light examination can help delineate areas of pigment loss, especially in patients with lighter skin types 3
While vitiligo diagnosis is often straightforward in classical presentations, atypical presentations may require expert assessment by a dermatologist 1
Blood tests for thyroid function and thyroid autoantibodies should be performed in all patients with vitiligo, especially when other autoimmune manifestations like EAC are present 1, 2

Recognition of the autoimmune connection between these conditions guides treatment approaches 1
For vitiligo, topical treatments include potent topical steroids (limited to 2-month trials due to risk of skin atrophy) and calcineurin inhibitors like pimecrolimus or tacrolimus which have better safety profiles 1
For widespread vitiligo, narrowband UVB phototherapy is recommended over PUVA due to greater efficacy 1
Monitoring for development of other autoimmune conditions is important in long-term follow-up 2

Failing to screen for thyroid disease in patients with vitiligo can miss an important treatable condition 1, 2
Extended use of potent topical steroids beyond 2 months can cause skin atrophy 1
Overlooking the psychological impact of these visible skin conditions, particularly vitiligo, which can significantly affect quality of life 4

The British Journal of Dermatology guidelines classify vitiligo into two main types: non-segmental (vitiligo vulgaris) and segmental vitiligo, distinguished by their distribution pattern, symmetry, and clinical behavior 5, 6

Non-segmental vitiligo (vitiligo vulgaris) is characterized by symmetrical depigmented patches that typically increase in size over time, representing the most common presentation of vitiligo, and can develop at any age with average onset around 20 years 5, 7
Segmental vitiligo is characterized by unilateral, asymmetrical depigmentation confined to one segment of the body, which may follow dermatome distribution or Blaschko's lines 5, 6

The British Journal of Dermatology guidelines recommend classifying vitiligo by disease activity, with stable disease characterized by no new lesions, no Koebner phenomenon, and no extension of existing lesions for at least 12 months 6, 8
Surgical treatments are reserved exclusively for stable disease with no progression for 12 months 6, 8, 7

Classical symmetrical presentations can be diagnosed confidently in primary care, while atypical presentations require referral to dermatology for expert assessment 8
Wood's light examination helps delineate pigment loss, particularly useful in lighter skin types 8
Non-segmental vitiligo typically requires long-term management with topical therapies or phototherapy depending on extent, while segmental vitiligo often requires more aggressive early treatment as it may stabilize quickly 6, 8
Localized disease can be treated with topical potent steroids or calcineurin inhibitors, and widespread disease can be treated with narrowband UVB phototherapy preferred over PUVA 8, 6, 7

Failing to assess disease activity before considering surgical interventions, which are contraindicated in active disease, is a common pitfall 6, 8
Vitiligo causes significant quality of life impairment regardless of classification, and its psychological impact should not be overlooked 5, 7

The British Journal of Dermatology guidelines emphasize classifying vitiligo by disease activity, which is clinically more relevant than traditional staging, with stable disease defined by no new lesions, no Koebner phenomenon, and no extension of existing lesions for at least 12 months 9
The Vitiligo European Task Force (VETF) system combines analysis of extent, stage of disease, and disease progression assessed by Wood's light examination, providing a comprehensive assessment of vitiligo 10
The Vitiligo Area Scoring Index (VASI) quantifies overall depigmented area and degree of repigmentation, correlating well with physician and patient assessments (P = 0.05 and P = 0.001, respectively) 10

Widespread disease requires narrowband UVB phototherapy, which is preferred over PUVA due to greater efficacy, as recommended by the British Journal of Dermatology 11
Surgical interventions are reserved exclusively for stable disease with no progression for 12 months, and should only be used for cosmetically sensitive sites, with segmental vitiligo achieving best surgical results with >75% repigmentation in 71% of cases 9, 12
Age under 20 years and focal/segmental disease show higher success rates with treatments such as suction blister transfer plus PUVA, with 50% achieving significant repigmentation 12
Active generalized vitiligo shows only 14% achieving 90-100% coverage with surgical techniques, compared to 90-100% in localized disease, highlighting the importance of disease stability in treatment selection 12

The British Journal of Dermatology guidelines highlight the importance of considering the psychological impact of vitiligo, which significantly impairs quality of life, particularly in women and those with darker skin 10
Failing to assess disease stability before considering surgical interventions is a common pitfall, as surgical interventions are absolutely contraindicated in active disease with progression within 12 months 9